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In a field on the west coast of Africa,
banana trees stand some 25 feet tall. The
trees' huge frondlike leaves shadow dusters
ofripening fruit, peels green in the midday
sun. Each tree supports up to 150 bananas,
enough to feed acrowd ofpeople.
In coming years, trees like these may
provide more than sweet nutrition. Bananas
could become the world's first edible vac-
cine. "It may sound unusual," says Charles
Arntzen, a plant biologist and president of
Cornell University's Boyce Thompson
Institute for Plant Research. "But you have
to realize that many people in the develop-
ing world don't have access to the equip-
ment needed for modern vaccines. They do
have access to agriculture. So plants could
be awayto delivervaccines."
According to the World Health
Organization (WHO), more than 2 mil-
lion children-most in the developing
world-die each year from diseases that
can be prevented with vaccines. Bacterial
diarrheas, which sicken adults but can
dehydrate and kill children, are a major
problem. Researchers at Boyce Thompson
hope to develop oral plant vaccines to pre-
vent deadly diarrhea caused by Escherichia
coli and Vibrio cholerabacteria.
Like injected vaccines, the
edible variety would not
cause disease, but would
train the body's immune
system to recognize
and attack a disease
bacteria or virus.
Unlike injected vac-
cines, however, the
edible ones would be
gist at Boyce Thompson. "If you can
instead produce the immunogenic protein
in an edible plant tissue, you can lower the
cost. I can envision growing large plots of
plants in a way that makes [vaccine] pro-
duction verycheap."
Scientists at Boyce Thompson hope to
use a straightforward bacterial vector
approach to engineer life-saving bananas.
First, they will splice the gene for an
immune system-stimulating disease protein
into Agrobacterium. When exposed to
banana cells, theAgrobacteium will shuttle
the gene inside. Researchers will then grow
the cells into mature plants bearing fruit
that, when eaten, confer immunity to the
particulardisease.
These researchers have already used this
technique to engineerpotatoeswith a mod-
ified E. coli protein from a bacterial strain
that normally causes severe diarrhea. Eating
the raw potatoes, mice developed antibod-
ies to the E. coli toxin. Theoretically,
humans who eat the potatoes should devel-
op similar immunity. "We've demonstrated
feasibility," Arntzen says. "Now, we want
to demonstrate efficacy." Arntzen and col-
laborators at a national vaccine testing cen-
ter hope to begin human clinical trials
with the E. coli-carrying potatoes
thisyear.
"It's very exciting work,"
says Joseph St. Geme, a
pediatrician at Wash-
ington University School
of Medicine in St.
Louis, Missouri. "There
inexpensive and easy to
distribute.
"Current recombinant-
vaccines are expensive
because they-need fermen-
tation and protein purifi- GoneshuttAe. Agrobacterium carry
cation," explains Hugh genesfor disease proteins into fruit
Mason, a molecular biolo- cells.(Source:HughS.Mason)
F is increasing evidence
that the oral immuniza-
tion route is going to be
effective. And it's as likely
to be effective with a
banana as with any other
oral method ofintroducing
anantigen."
At Scripps Research
Institute in La Jolla, Cali-
fornia7,TlW iologist Mich Hein is also u
studying oral vaccine delivery. Hein is
growing alfalfa spiked with a modified
cholera toxin, which should act as a vac-
cine when fed to mice. He hopes to study
the highly immunogenic cholera toxin as a
prelude to otherdiseases, particularly those
that affect cattle.
"If we can find out what makes the
modified cholera toxin an active oral vac-
cine in mice, we might be able to translate
that into other diseases and other ani-
mals," Hein explains. "For example, it
could be cheaper for the agriculture indus-
try to deliver vaccines this way. And once
we have addressed the safety and efficacy
issues in nonhuman populations, we could
move on to people."
John Clements, a microbiologist at
Tulane University who collaborates with
Arntzen, agrees. "The good thing about
cattle orsheep is that you can control their
dailydiet," Clements adds. "You can clone
an antigen into their alfalfa or hay feed-
stock, and the animals will consume large,
consistent quantities. It's verypractical."
Ultimately, the researchers envision
officials in the developing world distribut-
ing fresh vaccine-carrying fruit to villagers.
Medicinal bananas might sport a different
colored peel-thanks to an engineered
pigmentation gene-that distinguishes it
from normal fruit. "With simple distribu-
tion," Arntzen says, "we might be able to
do alot ofgood."
The PerfectVaccine
In 1992, WHO and other international
organizations launched the Children's
Vaccine Initiative, a cooperative effort to
promote vaccine research for the developing
world. That year, dunng a trip to Thailand,
Arntzen was standing near a floating market
when he noticedamotherrunningherfinger
alongthetopofabanana,Ilifngatasteofthe
fruit to her infant's lips. The scene stayed
with him. "Itjust seemed so obvious to me,"
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saysArntzen, then at Texas A&M University.
"Bananas would be the perfect food for an
oral vaccine." The fruit is cheap, abundant,
and often fed to children, he notes. "And
most importandy, it is eaten uncooked, so the
vaccinewouldnotbedestroyed byheating."
At the time, researchers elsewhere had
engineered a hepatitis B virus (HBV) vac-
cine into yeast cells. "I wondered whether
it might be possible to produce a similar
recombinant vaccine in plants," Arntzen
says. It was an unusual idea. "Some people
dismissed the idea as totally unworkable,"
Arntzen says. "They gave us a look like we
were naive plant molecular biologists who
didn't understand immunology."
Still, Arntzen decided to try. His lab
first chose tobacco, a well-understood
plant, to test the plant vaccine idea. They
spliced a gene encoding an HBV surface
protein into Agrobacterium. Invading the
tobacco cells, the Agrobacterium directed
the cells to produce the HBV antigen. The
researchers regenerated the cells into tobac-
co plants.
Inspecting electron micrographs of
tobacco tissue extracts, Arntzen was thrilled
at what he saw: tiny, viruslike particles of
HBV. "It was incredible. To be honest, I
almost expected the plants to degrade the
antigen. Plants usually do that to nonuseful
proteins. And here we
come along, putting in a
protein of a human
pathogen . . . it was very
exciting that itworked."
Arntzen and col-
leagues next crushed the
tobacco plants' leaves,
extracted the HBV anti-
gen, and injected it into
mice. Sure enough, the
mice developed antibod-
ies to the antigen.
Now that the lab
knew the technology
worked, they turned to a
well-known food crop7
the potato. Using their Voggie vectors
modified HBV antigen, vegetables: to gel
the researchers added a
DNA sequence that causes proteins to be
expressed in potato tubers. They used the
same process as before and achieved the
same result: antibodies surfaced.
Although injecting plant-produced vac-
cines in mice is a good way to test the con-
cept, researchers really want animals to
gain immunity by eating a vaccine in food.
So far, mice that eat HBV-tainted potatoes
have not responded with significant anti-
body production.
"We just don't know yet ifwe can get
[the response] with HBV through an oral
route," Arntzen says. On the other hand,
the researchers have documented antibody
response in mice feeding on potatoes laced
with the E. coli toxin. Why the difference?
It appears that the E. coli toxin, a potent
immune system stimulator, is better than
HBV at alerting immune cells secreted into
the digestive system. This makes sense,
given that the E. coliprotein causes a diges-
tive disorder.
The researchers are also pursuing pota-
to studies with Norwalk virus, which is
responsible for about halfthe outbreaks of
gastroenteritis in the United States. Mary
Estes, a molecular virologist at Baylor
College of Medicine in Houston, is a key
collaborator in the Norwalkwork.
"We had already produced the
Norwalk virus capsid protein in another
Children may soon have
for eating their fruits and
tvaccinated.
system [insect
cells] and knew it
self-assembled
into partides which
were immunogenic
when given orally to animals," Estes said.
"So I was optimistic that we could make
similar particles in plants, and this was a
great idea." At press time, the group's first
report showing that Norwalk virus ex-
pressed in potatoes is immunogenic had
been submitted for publication.
For all its potential, the potato remains
a somewhat impractical edible vaccine
crop. "For one thing, you really need
something that can be eaten raw," says
Gregory May, a plant biologist at Boyce
Thompson. "If you cook the potato, its
engineered proteins are going to denature
and lose their function. And who eats raw
potatoes?"
Enter the banana, a food almost always
eaten raw. "In the developing world," May
says, "people eat bananas all the time.
They make banana flour and banana beer.
And they feed bananas to young children."
Step by step, May and colleagues are
engineering a vaccine-carrying banana. Last
spring, the group reported its first mile-
stone: theysuccessfully engineered a marker
gene into the fruit. They will soon attempt
engineeringvaccine antigens as well.
The banana research involves
i collaboration with a research lab
_ in Irapuato, Mexico, which has
_ field facilities to grow the tropical
_ fruit. "We would like to establish
a collaboration with Mexico's
Ministry of Health," Arntzen
says. "They have a good infra-
structure for public education
. about health issues." In that
country, he notes, diarrheal dis-
ease is the number one killer of
Lz children under five.
Technical Hurdles
Three years ago, no one had ever
tried to engineer a vaccine-carrying plant.
"We're starting with near-zero informa-
tion on inserting foreign pharmacological
proteins in plants," Arntzen says. "So we
do a lot ofempirical groundwork." Much
ofthat work involves boosting gene expres-
sion. Often, an engineered disease gene
produces a protein in plant tissue, but at
levels too low to generate an immune
response ifthe plant were eaten.
"Gene expression
is a continuing chal-
lenge," notes Hein.
GEN_ One way researchers
icago,,,:1Ihope to maximize
expression is to learn
how some naturally
occurring genes be-
come highly expressed
in the first place.
"We're trying to
identify proteins present in abundance in
the banana," explains May. "Then we can
backtrack to look for the regulatory ele-
ments that determine the proteins' expres-
sion." Researchers would then attach the
DNA sequences that drive high gene
expression to their disease antigen gene.
Using this technique, the group increased
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E. co/i protein expression in potatoes ten-
fold, Mason says.
Once researchers get enough of a dis-
ease protein into a plant, the next chal-
lenge is to make sure an animal's immune
system responds to that protein. One
problem is oral tolerance. "Many antigens
that you eat in food do not give an
immune response," Mason says. "That's
because the body perceives the food anti-
gen as food, and the immune response is
essentially repressed."
To alert the immune system, the
researchers may try to pair vaccine disease
proteins with very strong oral immuno-
gens, like the cholera toxin or Norwalk
virus. These adjuvants may help stimulate
an immune response.
Meanwhile, a lot of questions remain.
"They range all the way from kitchen sci-
ence, like what happens to the protein
when you crush alfalfa, dry it, and make it
into food, to long-term immunization
issues," Hein says.
The next goal for plant vaccine engi-
neers is to demonstrate that protective
immunity is gained by eating an engi-
neered plant. So far, the experiments with
mice have shown only that they generate
antibodies when presented with a disease
antigen. These mice have never actually
encountered natural E. coli or HBV dis-
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eases, because animals don't get these
human diseases.
The only way to truly test whether a
plant vaccine confers protective immunity
is to deliver that plant to a human, who is
then exposed to the disease under investi-
gation. "This is the acid test," says Mason.
"In some cases, an antigen preparation
may stimulate immunoglobulins that neu-
tralize the antigen in the test tube and yet
provide little or no protection against the
disease. We are planning to begin some
human studies with the potatoes, initially
only to assess safety and immunogenicity
in humans, but later to assess protection."
Clinical trials should answer a host of
questions, including whether normal plant
proteins interfere with disease antigen
delivery or how well various immunizing
proteins act when taken orally. Clements,
for one, is confident the plant vaccine
technology will prevail. "It's going to take
some time to develop," he says. "But there
sure is a lot ofpotential."
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